Dr James Pang, Research Fellow
Turner Institute for Brain and Mental Health, Monash University
VICTORIA, AUSTRALIA
Bench Side Story continues with a Research Fellow at the Turner Institute for Brain and Mental Health, at Monash University in Melbourne, Victoria, Australia.
Dr James Pang received his PhD in Physics from the University of Sydney and completed his postdoctoral training in the Brain Modelling Group at QIMR Berghofer Medical Research Institute (Brisbane, Australia). He is currently a Research Fellow at the Turner Institute for Brain and Mental Health, School of Psychological Sciences. His research employs a multidisciplinary approach that combines biophysical models, neuroimaging, and connectivity to better understand the mechanisms of brain function in health, disease, and across species.
-
CASE STUDY Link between levels of extracellular vesicles in the blood and tissue damage caused by diseases
A landmark study led by WEHI and La Trobe University has found a potential new diagnostic marker that could be used to better detect the level of tissue damage in our bodies.
This study revealed, for the first time, a link between levels of EVs in the blood and tissue damage caused by diseases such as leukaemia.
Researchers hope to leverage the critical new insight to develop a blood test to monitor cancer patients with tissue damage, which could, in future, enhance treatment strategies for blood cancers and other diseases.
-
Dental care improvements using informatics and artificial intelligence
a member of the Scientific Advisory Committee for Dentroid, a startup in Australia aiming to revolutionise dentistry with laser technology. He has gained extensive experience in various roles at research-intensive institutions across three different continents.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
